After nearly a year off the shelves, GlaxoSmithKline's diet pill alli--recalled after reports of tampering--is back in most U.S. stores, and it's got some updates that should make any future tampering easier to spot.
Roche closed its Clifton, NJ, campus in 2013 and hopes to be free of the property this year. But some area residents want to slap the Swiss drugmaker with a lawsuit before it leaves town, concerned about whether the site has caused environmental issues over the years that will make it difficult for them to sell their homes.
SINGAPORE-- Hong Kong health facilities say a monthlong outbreak of H3N2 influenza has drained their supply of the drug they use for treatment, Roche's Tamiflu.
SINGAPORE-- One of the world's most prestigious medical journals called for India to abandon its current proposal to change the way it regulates drugs and come up with a new plan.
The summit meeting between President Barack Obama and India Prime Minister Narendra Modi resulted in no breakthroughs, such as on intellectual property, but did lead to about a dozen smaller agreements on various issues affecting the pharmaceutical industries.
India's state of Himachal Pradesh, known as Asia's pharmaceutical hub, is taking steps to make its bulk-drug industry more attractive to foreign and other investors, but finds attempting to do so a hard slog. The action, and that of other states, is considered key to reducing India's reliance on imports of active pharmaceutical ingredients, mainly from China.
Sanofi and Regeneron are hard at work on a number of promising monoclonal antibodies, but Sanofi needs more manufacturing capacity to produce them. Instead of building its own like some of its peers, the French company has struck a deal to tap into a Boehringer Ingelheim plant in Germany.
Given that the industry has hundreds of billions of dollars invested in plants that do batch manufacturing, it has been hard for the industry to commit to a new way of making drugs, even one with the potential to cut costs dramatically. But at a major conference in May, the industry coalesced around the need to adopt continuous manufacturing.
AstraZeneca has been touting its pipeline full of promising products as a reason it will return to growth by 2017 and has no need to hook up with Pfizer. As if to put an exclamation point on that declaration, the company says it will kick off a U.S. expansion that will add 300 jobs so it can realize that potential.
Merck may soon be the next Big Pharma to step into the Ebola vaccine arena.